THERAPY DOSSIER · th-9d4016d8051d

AREDS antioxidant mineral formulation with or without rosemary extract, carnosic acid or zinc oxide

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29062223 ↗2017Mixed findings

Enhancing the efficacy of AREDS antioxidants in light-induced retinal degeneration.

RatRadiationSprague-DawleyMaleOral (dietary supplement)Daily dietary supplement on a small cracker at daily recomm…Daily supplementation before acute intense light exposure (one week of AREDS pl…

Model: Photo-oxidative retinal damage: 6 hours of intense white light (9,000 lux) after 6 weeks rearing in low (20 lux) or high (200 lux) cyclic light

AREDS alone and zinc oxide alone at daily recommended levels were ineffective, whereas AREDS plus rosemary and zinc oxide plus rosemary reduced retinal damage and AREDS plus carnosic acid preserved visual cell proteins and retinal DNA

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…